Artelo Biosciences Announces Re-election of Directors and Increase in Authorized Shares

Artelo Biosciences, Inc. held its Annual Meeting of Stockholders on July 17, 2026. During the meeting, stockholders voted on several key proposals. Three Class III directors—Gregory R. Reyes, M.D., Ph.D., Tamara A. Favorito, and Gregory D. Gorgas—were re-elected to serve until the 2029 annual meeting. Additionally, stockholders approved an amendment to the company's Articles of Incorporation to significantly increase the number of authorized shares of common stock from 166,666,667 to 500,000,000. Finally, the issuance of more than 20% of the company's outstanding common stock pursuant to an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5 was approved. Approximately 41.2% of the outstanding shares were represented at the meeting. No clinical trial updates or upcoming result dates were disclosed in this filing.